Suppr超能文献

区分“低雌激素受体表达”病例与三阴性乳腺癌的临床和病理特征

The Clinical and Pathological Characteristics That Differentiate Cases With "Low Estrogen Receptor Expression" From Triple-Negative Breast Cancer.

作者信息

Karaali Cem, Emiroğlu Mümin, Değirmenci Mustafa, Keser Murat, Salimoğlu Semra, Kelten Talu Canan

机构信息

Department of General Surgery, İzmir Faculty of Medicine, University of Health Sciences Turkey, İzmir, Turkey.

Department of Medical Pathology, İzmir Faculty of Medicine, University of Health Sciences Turkey, İzmir, Turkey.

出版信息

Eur J Breast Health. 2023 Dec 27;20(1):19-24. doi: 10.4274/ejbh.galenos.2023.2023-6-3. eCollection 2024 Jan.

Abstract

OBJECTIVE

Estrogen receptor (ER) expression is an immunohistochemical marker that is examined in all invasive breast cancers and has prognostic and predictive value. ER-positive breast cancers refer to those that show positivity for ER at 1% cellular expression or higher. The American Society of Clinical Oncology/College of American Pathologists guidelines suggest using the term "low ER-positive breast cancer" for tumors with ER expression between 1% and 10%. Low ER-positive breast cancers exhibit similarities, in terms of disease-free survival and overall survival rates, to triple-negative breast cancers (TNBCs) rather than ER-positive breast cancers. In this study, our aim was to compare the clinicopathological characteristics of low ER-positive breast cancer cases diagnosed and followed in our clinic with TNBCs.

MATERIALS AND METHODS

A total of 26 cases of low ER-positive breast cancer diagnosed at University of Health Sciences Turkey, İzmir Tepecik Training and Research Hospital between 2010 and 2016 were retrieved from hospital records. The relevant histopathology slides and blocks were retrieved and re-evaluated retrospectively through microscopic examination. Thirteen cases that met the criteria were included in the study. Additionally, a consecutive series of 13 TNBC cases that did not receive neoadjuvant treatment within the same time period were identified.

RESULTS

In the low ER-positive group, the presence of tumor necrosis, as well as histological grade, nuclear grade and Ki-67 proliferation index were significantly lower compared to the TNBC group. Ductal carcinoma (DCIS) was significantly more common in the low ER-positive group compared to the TNBC group. There were no significant differences between the two groups in terms of tumor size, histological tumor type, axillary lymph node involvement, tumor margins, peritumoral and intratumoral inflammation, local recurrence, distant metastasis, survival, and other characteristics.

CONCLUSION

Although our study consisted of a small number of cases, some features showed significant differences between low ER-positive breast cancers and TNBCs. Histological and nuclear grades, as well as the presence of a DCIS component, were associated with low ER-positive breast cancer. In contrast, the presence of tumor necrosis, as well as Grade 3 features and a high Ki-67 proliferation index indicated TNBC.

摘要

目的

雌激素受体(ER)表达是一种免疫组化标志物,在所有浸润性乳腺癌中均会检测,具有预后和预测价值。ER阳性乳腺癌是指那些细胞表达率为1%或更高时显示ER阳性的乳腺癌。美国临床肿瘤学会/美国病理学家学会指南建议,对于ER表达在1%至10%之间的肿瘤,使用“低ER阳性乳腺癌”这一术语。低ER阳性乳腺癌在无病生存率和总生存率方面,与三阴性乳腺癌(TNBC)更为相似,而非ER阳性乳腺癌。在本研究中,我们的目的是比较在我们诊所诊断并随访的低ER阳性乳腺癌病例与TNBC的临床病理特征。

材料与方法

从土耳其伊兹密尔特佩奇克培训与研究医院健康科学大学2010年至2016年期间诊断的低ER阳性乳腺癌病例中,共检索出26例,并从医院记录中获取相关组织病理学切片和蜡块,通过显微镜检查进行回顾性重新评估。符合标准的13例病例纳入研究。此外,确定了同一时期连续的13例未接受新辅助治疗的TNBC病例。

结果

在低ER阳性组中,与TNBC组相比,肿瘤坏死的存在以及组织学分级、核分级和Ki-67增殖指数显著更低。与TNBC组相比,导管原位癌(DCIS)在低ER阳性组中明显更常见。两组在肿瘤大小、组织学肿瘤类型、腋窝淋巴结受累情况、肿瘤边缘、瘤周和瘤内炎症、局部复发、远处转移、生存率及其他特征方面无显著差异。

结论

尽管我们的研究病例数量较少,但低ER阳性乳腺癌与TNBC之间的一些特征存在显著差异。组织学和核分级以及DCIS成分的存在与低ER阳性乳腺癌相关。相比之下,肿瘤坏死的存在以及3级特征和高Ki-67增殖指数提示为TNBC。

相似文献

1
The Clinical and Pathological Characteristics That Differentiate Cases With "Low Estrogen Receptor Expression" From Triple-Negative Breast Cancer.
Eur J Breast Health. 2023 Dec 27;20(1):19-24. doi: 10.4274/ejbh.galenos.2023.2023-6-3. eCollection 2024 Jan.
4
A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
Indian J Pathol Microbiol. 2020 Jul-Sep;63(3):388-396. doi: 10.4103/IJPM.IJPM_657_19.
5
The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
Indian J Pathol Microbiol. 2021 Oct-Dec;64(4):671-676. doi: 10.4103/IJPM.IJPM_606_20.
10
Overview of resistance to systemic therapy in patients with breast cancer.
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.

引用本文的文献

1
H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.
NPJ Digit Med. 2025 Jul 2;8(1):384. doi: 10.1038/s41746-025-01741-9.

本文引用的文献

1
Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Front Endocrinol (Lausanne). 2022 Nov 24;13:1015388. doi: 10.3389/fendo.2022.1015388. eCollection 2022.
5
Characterization of estrogen receptor-low-positive breast cancer.
Breast Cancer Res Treat. 2021 Jul;188(1):225-235. doi: 10.1007/s10549-021-06148-0. Epub 2021 Mar 10.
7
Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer.
Eur J Breast Health. 2019 Jul 1;15(3):141-146. doi: 10.5152/ejbh.2019.4890. eCollection 2019 Jul.
9
10
Low ER+ breast cancer: Is this a distinct group?
Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验